Dicot Investor Relations Material

Dicot AB is a pharmaceutical company focused on the development of lifestyle drugs, primarily addressing sexual health issues such as erectile dysfunction and premature ejaculation. Founded in 2021, Dicot conducts drug discovery and development aimed at improving quality of life for patients with these conditions. The company's main research involves the drug candidate LIB-01, which is in the early stages of clinical trials. Dicot AB is a private entity and maintains active operations, contributing to the healthcare and drug development sectors. The company is headquartered in Uppsala, Sweden, and its shares are listed on the Stockholm Stock Exchange.